We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1326
Amphastar Pharmaceuticals
AMPH
$869M
| $1.23M | ﹤0.01% |
35,290
+21,791
| +161% | +$778K |
|
1327
Global Industrial
GIC
$1.5B
| $1.23M | ﹤0.01% |
36,378
-7,046
| -16% | -$230K |
|
1328
Applied Industrial Technologies
AIT
$13B
| $1.22M | ﹤0.01% |
12,701
+2,337
| +23% | +$236K |
|
1329
ABM Industries
ABM
$2.83B
| $1.22M | ﹤0.01% |
28,063
-8,402
| -23% | -$389K |
|
1330
Paysafe
PSFE
$353M
| $1.22M | ﹤0.01% |
53,296
-57,831
| -52% | -$1.87M |
|
1331
Academy Sports + Outdoors
ASO
$3.07B
| $1.22M | ﹤0.01% |
34,195
-33,039
| -49% | -$1.21M |
|
1332
Usana Health Sciences
USNA
$254M
| $1.21M | ﹤0.01% |
16,746
-3,575
| -18% | -$266K |
|
1333
Apogee Enterprises
APOG
$904M
| $1.21M | ﹤0.01% |
30,788
+8,711
| +39% | +$373K |
|
1334
Valley National Bancorp
VLY
$8.16B
| $1.21M | ﹤0.01% |
117,684
-409,193
| -78% | -$4.86M |
|
1335
Seres Therapeutics
MCRB
$46.6M
| $1.21M | ﹤0.01% |
17,566
+4,246
| +32% | +$366K |
|
1336
Atlassian
TEAM
$39.1B
| $1.2M | ﹤0.01% |
6,417
-8,930
| -58% | -$1.91M |
|
|
EVBG
1337
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $1.2M | ﹤0.01% |
43,831
-154,148
| -78% | -$6.25M |
|
1338
Enova International
ENVA
$6.4B
| $1.2M | ﹤0.01% |
41,501
+12,675
| +44% | +$419K |
|
1339
Flex
FLEX
$45.2B
| $1.19M | ﹤0.01% |
109,394
+1,453
| +1% | +$18K |
|
1340
Nature's Sunshine
NATR
$281M
| $1.19M | ﹤0.01% |
111,511
+41,510
| +59% | +$577K |
|
|
NPKI
1341
NPK International
NPKI
$1.18B
| $1.19M | ﹤0.01% |
383,769
+177,653
| +86% | +$680K |
|
1342
Iron Mountain
IRM
$36.4B
| $1.18M | ﹤0.01% |
24,589
-1,676
| -6% | -$88.2K |
|
1343
Cavco Industries
CVCO
$4.57B
| $1.18M | ﹤0.01% |
6,023
-849
| -12% | -$189K |
|
1344
First Busey Corp
BUSE
$2.57B
| $1.18M | ﹤0.01% |
51,586
+14,450
| +39% | +$336K |
|
1345
Delek US
DK
$3.92B
| $1.18M | ﹤0.01% |
45,601
+25,562
| +128% | +$690K |
|
1346
Winnebago Industries
WGO
$927M
| $1.18M | ﹤0.01% |
24,248
-2,260
| -9% | -$117K |
|
1347
Ducommun
DCO
$2.98B
| $1.18M | ﹤0.01% |
27,302
+18,449
| +208% | +$884K |
|
1348
JELD-WEN Holding
JELD
$164M
| $1.17M | ﹤0.01% |
80,351
+23,896
| +42% | +$434K |
|
1349
STAAR Surgical
STAA
$1.24B
| $1.17M | ﹤0.01% |
16,574
-64,403
| -80% | -$4.15M |
|
1350
Scansource
SCSC
$1.05B
| $1.17M | ﹤0.01% |
37,564
+2,107
| +6% | +$73.9K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.